Atlas Trials

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Clinical trial NCT03016819 · RECRUITING

Trial details

NCT number
NCT03016819
Sponsor
Advenchen Laboratories, LLC
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Alveolar Soft Part SarcomaLeiomyosarcomaSynovial SarcomaSoft-Tissue Sarcoma
Start date
2017-08-15
Primary completion
2027-12-01
Enrollment
325

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.